Tandem Diabetes Care(NASDAQ) TNDM

Tandem Diabetes Care, Inc. helps people manage their blood sugar. Its pumps replace manual injections for daily insulin delivery. Smart software adjusts doses automatically using real-time data.

Smart Pumps and Connected Apps

• Insulin Pumps: Portable hardware like the t:slim X2 and Tandem Mobi that deliver insulin; generated $83.0 million in U.S. sales during the second quarter of 2026.
• Pump Supplies: Single-use items including cartridges and infusion sets; accounted for $96.3 million in U.S. sales for the three-month period ended June 30, 2026.
• Control-IQ Technology: Smart software that predicts and helps prevent high or low blood sugar using wearable sensor data.
• Tandem Source: A web-based data platform that displays therapy results for patients, caregivers, and healthcare professionals.

Expansion and Future Tech

• Launched Control-IQ+ globally in 2025 as the company's third Automated Insulin Delivery (AID) algorithm.
• Submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026 for a tubeless pump version.
• Acquired technology for the Sigi Patch Pump to develop smaller, next-generation wearable devices.
• Entered a settlement agreement with Roche during the second quarter of 2025 regarding patent litigation costs.
• Transitioned to direct servicing of rental customers in Switzerland during the first half of 2026.

What Makes Tandem Stand Out

Tandem differentiates itself by offering the only predictive algorithm with AutoBolus, a feature that provides automatic corrective insulin doses. The company is also shifting toward a pharmacy model where customers pay as they go for treatment instead of paying upfront.

Key Figures and Results

• Total sales reached $254.6 million for the three months ended June 30, 2026, up from $240.7 million in 2025.
• Gross margin improved to 57% in the second quarter of 2026 compared to 52% year over year.
• U.S. pump shipments grew to more than 22,000 units in the three-month period ended June 30, 2026.
• Cash and short-term investments totaled $456.0 million as of June 30, 2026.

Bottom Line

Tandem has evolved from a single-pump company to a multi-platform technology provider with flexible payment options. Its transition toward tubeless devices and pharmacy distribution reflects a focus on broader user access and long-term recurring revenue.